Sun Pharma ratings reaffirmed: ICRA AAA for 2026 NCD

What the latest rating actions say

Sun Pharmaceutical Industries Limited reported multiple credit rating updates dated 13 Oct 2026, with agencies reaffirming ratings across key borrowing instruments. ICRA reaffirmed ratings and assigned [ICRA]AAA (Stable) for a fresh non-convertible debenture (NCD) of Rs 15,000 crore. Separately, Sun Pharma Laboratories Limited also saw its rating reaffirmed on the same date, according to the disclosures.

These actions matter for investors and debt market participants because they indicate how rating agencies view the company’s credit profile and its ability to access funding at competitive costs. The reaffirmations also follow earlier rating developments linked to the Organon acquisition.

ICRA’s action on the fresh Rs 15,000 crore NCD

In the stated rationale, ICRA reaffirmed Sun Pharmaceutical Industries Limited’s ratings and assigned AAA (Stable) for a fresh Rs 15,000 crore NCD. The update is presented as a reaffirmation with a stable outlook, indicating ICRA’s view that the issuer’s credit profile remains consistent with the top long-term rating category.

The information provided does not specify the tenor, pricing, or intended use of proceeds for the NCD. But the size of the proposed issuance makes it a material funding program, and the rating level is typically relevant for institutional buyers assessing risk and portfolio limits.

Sun Pharma Laboratories: reaffirmation noted

The disclosure also lists Sun Pharma Laboratories Limited with a “rating reaffirmed” note dated 13 Oct 2026. No additional details were provided in the text on the instruments covered, the agency behind the action, or any change in outlook.

Given the limited detail, the key takeaway is that the rating status is described as reaffirmed rather than upgraded or downgraded.

International issuer ratings: Moody’s and S&P

Sun Pharmaceutical Industries Limited has been assigned international issuer credit ratings of Baa1 by Moody’s and BBB+ by S&P, both described as investment-grade. The disclosure notes that these ratings reflect the company’s strong financial profile.

The filing history further states that the ratings reflect the company’s strong business position post-Organon acquisition, alongside expectations of deleveraging and healthy cash flow. These international ratings were communicated on 08 September 2026, as per the provided text.

CRISIL reaffirms AAA and removes “Watch Developing”

CRISIL reaffirmed Sun Pharmaceutical Industries’ long-term bank facilities rating at ‘CRISIL AAA/Stable’. The update also states that CRISIL has removed the “Rating Watch with Developing Implications” status, which had been associated with the long-term rating earlier.

A separate news-style note reiterates that Sun Pharmaceutical Industries announced CRISIL’s removal of the watch status and reaffirmation of the long-term bank facilities rating at CRISIL AAA/Stable. The removal indicates CRISIL has completed its assessment related to the acquisition and has “resolved the rating watch,” as described in the text.

How the Organon acquisition featured in prior rating watch actions

The filing history states that CRISIL placed the long-term rating on “Rating Watch with Developing Implications” following the announcement of the Organon & Co. acquisition on April 27, 2026. ICRA, however, reaffirmed its ‘AAA(Stable)’ rating while taking note of the acquisition.

Later, CRISIL removed the watch status after completing its assessment of the acquisition, while reaffirming ratings. The disclosure does not provide transaction values or post-deal leverage metrics, but it directly links the watch period and its resolution to the acquisition assessment.

Key ratings and instruments at a glance

What this means for debt investors and the company

Across the disclosures, the consistent theme is reaffirmation at the top domestic long-term rating level (AAA) and top short-term level (A1+), alongside investment-grade international issuer ratings. For debt investors, reaffirmations and a “Stable” outlook typically support the view that the issuer’s credit risk profile has not materially weakened based on the agency’s current assessment.

The removal of CRISIL’s “Rating Watch with Developing Implications” is also a concrete event. The text explicitly links the watch to the Organon acquisition announcement and says the watch was resolved after CRISIL completed its assessment.

Timeline of the rating-related milestones in the disclosure

Conclusion

Sun Pharmaceutical Industries’ latest disclosures show reaffirmed ratings across agencies, including ICRA’s AAA (Stable) for a fresh Rs 15,000 crore NCD and CRISIL’s reaffirmed AAA/Stable for long-term bank facilities with the watch status removed. Internationally, Moody’s and S&P have assigned investment-grade issuer ratings with stable outlooks, citing the company’s financial profile and post-acquisition positioning. The next checkpoints for markets will typically be further debt issuance details (if any) and any subsequent rating agency updates tied to ongoing disclosures.